Caveolin-1 in Breast Cancer: Single Molecule Regulation of Multiple Key Signaling Pathways |
Anwar, Sumadi Lukman
(Department of Surgery, Faculty of Medicine, Universitas Gadjah Mada)
Wahyono, Artanto (Department of Surgery, Faculty of Medicine, Universitas Gadjah Mada) Aryandono, Teguh (Department of Surgery, Faculty of Medicine, Universitas Gadjah Mada) Haryono, Samuel J (Mochtar Riady Comprehensive Cancer Center(MRCCC) Siloam Hospital Semanggi) |
1 | Witkiewicz AK, Kline J, Queenan M, et al (2011). Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle, 10, 1794-1809. DOI |
2 | Witkiewicz AK, Dasgupta A, Nguyen K, et al (2009). Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther, 8, 1071-9. DOI |
3 | Wu P, Qi B, Zhu H, et al (2007). Suppression of staurosporinemediated apoptosis in Hs578T breast cells through inhibition of neutral-sphingomyelinase by caveolin-1. Cancer Lett, 256, 64-72. DOI |
4 | Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R, (2012). mTOR inhibitors in breast cancer: A systematic review. Gynecol Oncol, 127, 662-72. DOI |
5 | Zhang EY, Cristofanilli M, Robertson F, et al (2013). Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. J Proteome Res, 12, 2805-17. DOI |
6 | Zou W, McDaneld L, Smith LM, (2003). Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. AntiCancer Res, 23, 4581-6. |
7 | Agelaki S, Spiliotaki M, Markomanolaki H, et al (2009). Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther, 8, 1470-7. DOI |
8 | Bhowmick NA, Neilson EG, Moses HL (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432, 332-7. DOI |
9 | Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, et al 2010. The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle, 9, 1960-71. DOI |
10 | Bucci M, Gratton JP, Rudic RD, et al (2000). In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med, 6, 1362-7. DOI |
11 | Burke P, Schooler K, Wiley HS (2001). Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell, 12, 1897-1910. DOI |
12 | Cirri P, Chiarugi P (2011). Cancer associated fibroblasts : the dark side of the coin. Am J Cancer Res, 1, 482-97. |
13 | Cai C, Chen J (2004). Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int J Cancer, 111, 522-9. DOI |
14 | Carroll JS, Meyer CA, Song J, et al (2006). Genome-wide analysis of estrogen receptor binding sites. Nat Genet, 38, 1289-97. DOI |
15 | Castello-Cros R, Bonuccelli G, Molchansky A, et al (2011). Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle, 10, 2021-34. DOI |
16 | Clemons M, Goss P (2001). Estrogen and the risk of breast cancer. NEJM, 344, 276-285. DOI |
17 | Cohen AW, Razani B, Wang XB, et al (2003). Caveolin-1- deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol, 285, C222-5. DOI |
18 | Dong X, Mao S, Wen H (2013). Upregulation of proinflammatory genes in skin lesions may be the cause of keloid formation (Review). Biomed Rep, 1, 833-6. |
19 | El-Gendi SM, Mostafa MF, El-Gendi AM, et al (2012). Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res, 18, 459-69. DOI |
20 | Elsheikh SE, Green AR, Rakha EA, et al (2008). Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer, 99, 327-34. DOI |
21 | Van den Eynden GG, Van Laere SJ, Van der Auwera I, et al (2006).Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat, 95, 219-28. DOI |
22 | Fiucci G, Ravid D, Reich R, Liscovitch M, et al (2002). Caveolin-1 inhibits anchorage-independent growth anoikis and invasiveness in MFC-7 human breast cancer cells. Oncogene, 21, 2365-2375. DOI |
23 | Fielding PE, Chau P, Liu D, Spencer TA, Fielding CJ, (2004). Mechanism of platelet-derived growth factor-dependent caveolin-1 phosphorylation: relationship to sterol binding and the role of serine-80. Biochemistry, 43, 2578-86. DOI |
24 | Finn RS, Dering J, Ginther C (2007). Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat, 105, 319-26. DOI |
25 | Finn RS, Aleshin A, Dering J, et al (2013). Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology, 57, 1838-46. DOI |
26 | Fujita Y, Maruyama S, Kogo H, Matsuo S, Fujimoto T (2004). Caveolin-1 in mesangial cells suppresses MAP kinase activation and cell proliferation induced by bFGF and PDGF. Kidney Int, 66, 1794-04. DOI |
27 | Giusiano S, Cochet C, Filhol O, et al (2011). Protein kinase subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays. Eur J Cancer, 47, 792-801. DOI |
28 | Glait C, Ravid D, Lee SW, Liscovitch M, Werner H (2006). Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells. FEBS Lett, 580, 5268-74. DOI |
29 | Goetz JG, Minguet S, Navarro-Lerida I, et al (2011). Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell, 146, 148-63. DOI |
30 | Gupta R, Toufaily C, Annabi B (2014). Caveolin and cavin family members: dual roles in cancer. Biochimie, 107, 188-202. DOI |
31 | Hayashi K, Matsuda S, Machida K, et al (2001). Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res, 61, 2361-64. |
32 | Hino M, Doihara H, Kobayashi K, Aoe M, Shimizu N (2003). Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today, 33, 486-90. |
33 | Jezierska-Drutel A, Rosenzweig SA, Neumann CA, et al (2013). Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res, 119, 107-25. DOI |
34 | Joglekar M, Elbazanti WO, Weitzman MD, Lehma H, van Golen KL (2015). Caveolin-1 mediates inflamatory breast cancer cell invasion via the Akt1 pathway and RhoC GTPase. J Cell Biochem, 116, 923-33. DOI |
35 | Kiss AL (2012). Caveolae and the regulation of endocytosis. Adv Exp Med Biol, 729, 14-28. DOI |
36 | Koo JS, Park S, Kim SI, Lee S, Park BW (2011). The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol, 32, 787-99. DOI |
37 | Lajoie P, Nabi IR (2010). Lipid rafts, caveolae, and their endocytosis. Int Rev Cell Mol Biol, 282, 135-63. DOI |
38 | Lavie Y, Fiucci G, Liscovitch M (2001). Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev, 49, 317-23. DOI |
39 | Lee H, Park DS, Razani B, et al (2002). Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol, 161, 1357-69. DOI |
40 | Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE, (1998). Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 16, 1391-97. DOI |
41 | Ma X, Liu L, Nie W, et al (2013). Prognostic role of caveolin in breast cancer: a meta-analysis. Breast, 22, 462-9. DOI |
42 | Maldonado-Báez L, Williamson C, Donaldson JG (2013). Clathrin-independent endocytosis: A cargo-centric view. Exp Cell Res, 319, 2759-69. DOI |
43 | Martinez-Outschoorn U, Sotgia F, Lisanti MP (2014). Tumor microenvironment and metabolic synergy in breast cancers: Critical importance of mitochondrial fuels and function. Semin Oncol, 41, 195-216. DOI |
44 | Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker- Menezes D, et al (2010). Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NF activation in the tumor stromal microenvironment. Cell Cycle, 9, 3515-33. DOI |
45 | Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, et al (2011). Cytokine production and inflammation drive autophagy in the tumor microenvironment: Role of stromal caveolin-1 as a key regulator. Cell Cycle, 10, 1784-93. DOI |
46 | Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, et al (2010). Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 9, 2423-33. DOI |
47 | Martinez-Outschoorn UE, Sotgia F, Lisanti MP, (2015). Caveolae and signalling in cancer. Nat Rev Cancer, 15, 225-37. DOI |
48 | Mercier I, Lisanti M (2012). Caveolin-1 and breast cancer: a new clinical perspective. Adv Exp Med Biol, 729, 83-94. DOI |
49 | Mercier I, Camacho J, Titchen K, et al (2012). Caveolin-1 and accelerated host aging in the breast tumor microenvironment: Chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol, 181, 278-93. DOI |
50 | Mercier I, Casimiro MC, Wang C, et al (2008). Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther, 7, 1212-25. DOI |
51 | Mercier I, Lisanti MP (2012). Caveolin-1 and breast cancer: a new clinical perspective. caveolins and caveolae: roles in signaling and disease mechanisms. Adv Exp Med Biol, 729, 83-94. DOI |
52 | Mineo C, Gill GN, Anderson RGW, (1999). Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem, 274, 30636-43. DOI |
53 | Orom UA, Lim MK, Savage JE, et al (2012). MicroRNA-203 regulates caveolin-1 in breast tissue during caloric restriction. Cell Cycle, 11, 1291-5. DOI |
54 | Otranto M, Sarrazy V, Bonte F, et al (2012). The role of the myofibroblast in tumor stroma remodeling. Cell Adh Mig, 6, 203-19. DOI |
55 | Park DS, Lee H, Frank PG, et al (2002). Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell, 13, 3416-30. DOI |
56 | Park JH, Han HJ (2009). Caveolin-1 plays important role in EGFinduced migration and proliferation of mouse embryonic stem cells: involvement of PI3K/Akt and ERK. Am J Physiol Cell Physiol, 297, 935-44. DOI |
57 | Patani N, Lambros MB, Natrajan R, et al (2012). Non-existence of caveolin-1 gene mutations in human breast cancer. Breast Cancer Res Treat, 131, 307-10. DOI |
58 | Park JH, Lee MY, Han HJ, et al (2009). A potential role for caveolin-1 in estradiol-17beta-induced proliferation of mouse embryonic stem cells: involvement of Src, PI3K/Akt, and MAPKs pathways. Int J Biochem Cell Biol, 41, 659-65. DOI |
59 | Park SS, Kim JE, Kim YA, Kim YC, Kim SW (2005). Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology, 47, 625-30. DOI |
60 | Park WY, Park JS, Cho KA, et al (2000). Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem, 275, 20847-52. DOI |
61 | Patani N, Martin LA, Reis-Filho JS, Dowsett M, (2012). The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat, 131, 1-15. DOI |
62 | Pavlides S, Tsirigos A, Migneco G, et al (2010). The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle, 9, 3485-505. DOI |
63 | White BP, Molloy MP, Zhao H, et al (2013). Extranuclear ERalpha is associated with regression of T47D PKCalphaoverexpressing, tamoxifen-resistant breast cancer. Mol Cancer, 12, 34. DOI |
64 | Perrone G, Altomare V, Zagami M, et al (2009). Caveolin-1 expression in human breast lobular cancer progression. Mod Pathol, 22, 71-8. DOI |
65 | Qian N, Ueno T, Kawaguchi-Sakita N, et al (2011). Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci, 102, 1590-6. DOI |
66 | Sagara Y, Mimori K, Yoshinaga K, et al (2004). Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer, 91, 959-65. |
67 | Rao X, Evans J, Chae H, et al (2012). CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene, 32, 4519-28 |
68 | Ren M, Liu F, Zhu Y, et al (2014). Absence of caveolin-1 expression in carcinoma associated fibroblast of invasive micropapollary carcinoma of the breast predicts poor patient outcome. Virchows Arch, 465, 291-8. DOI |
69 | Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J, (2006). Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat, 99, 85-90. DOI |
70 | Savage K, Lambros MB, Robertson D, et al (2007). Caveolin 1 is overexpressed and amplified in a subset of basallike and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res, 13, 90-101. DOI |
71 | Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG, Lisanti MP, (1999). Caveolin-1 potentiates estrogen receptor (ER ) signaling. Caveolin-1 drives ligand-independent nuclear translocation and activation of ER . J Biol Chem, 274, 33551-6. DOI |
72 | Schlegel A, Wang C, Pestell RG, Lisanti MP, (2001). Ligandindependent activation of oestrogen receptor alpha by caveolin-1. Bioch J, 359, 203-10. DOI |
73 | Sekhar SC, Kasai T, Satoh A, et al (2013). Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J Cancer, 4, 391-401. DOI |
74 | Simpkins SA, Hanby AM, Holliday DL, Speirs V, (2012). Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol, 227, 490-8. DOI |
75 | Senetta R, Stella G, Pozzi E, et al (2013). Caveolin-1 as a promoter of tumour spreading: When, how, where and why. J Cell Mol Med, 17, 325-36. DOI |
76 | Shajahan AN, Dobbin ZC, Hickman FE, Dakshanamurthy S, Clarke R, (2012). Tyrosine-phosphorylated caveolin-1 (Tyr- 14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal Kinase (JNK). J Biol Chem, 287, 17682-92. DOI |
77 | Siegel R, Ma J, Zou Z, Jemal A, (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. DOI |
78 | Sloan EK, Ciocca DR, Pouliot N, et al (2009). Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol, 174, 2035-43. DOI |
79 | Sloan EK, Stanley KL, Anderson RL, (2004). Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene, 23, 7893-7. DOI |
80 | Sotgia F (2012). Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. Annual Review of Pathology: Mechanisms of Disease, 7, 423-467. DOI |
81 | Sotgia F, Martinez-Outschoorn UE, Howell A, et al (2006). Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res, 66, 10647-51. DOI |
82 | Sotgia F, Martinez-Outschoorn UE, Pavlides S, et al (2011). Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Br Cancer Res, 13, 213. DOI |
83 | Thomas NB, Hutcheson IR, Campbell L, et al (2010). Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat, 119, 575-91. DOI |
84 | Syeed N, Husain SA, Abdullah S, et al (2010). Caveolin-1 promotes mammary tumorigenesis: Mutational profile of the Kashmiri population. Asian Pac J Cancer Prev, 11, 689-96. |
85 | Syeed N, Husain SA, Abdullah S, et al (2010). Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population. Asian Pac J Cancer Prev, 11, 1099-105. |
86 | Tagawa A, Mezzacasa A, Hayer A, et al (2005). Assembly and trafficking of caveolar domains in the cell: Caveolae as stable, cargo-triggered, vesicular transporters. J Cell Biol, 170, 769-79. DOI |
87 | Tian F, Wu H, Li Z, et al (2009). Activated PKCalpha/ERK1/2 signaling inhibits tamoxifen-induced apoptosis in C6 cells. Cancer Invest, 27, 802-8. DOI |
88 | Trimmer C, Sotgia F, Whitaker-Menezes D, et al (2011). Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: A new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther, 11, 383-94. DOI |
89 | Tryfonopoulos D, Walsh S, Collins DM, et al (2011). Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol, 22, 2234-40. DOI |
90 | Wang XX, Wu Z, Huang HF, et al (2013). Caveolin-1, through its ability to negatively regulate TLR4, is a crucial determinant of MAPK activation in LPS-challenged mammary epithelial cells. Asian Pac J Cancer Prev, 14, 2295-9. DOI |
91 | Williams TM, Medina F, Badano I, et al (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem, 279, 51630-46. DOI |
92 | Wang Y, Yu J, Zhan Q (2008). BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness. Biochem Biophys Res Commun, 370, 201-6. DOI |
93 | Wang Z, Wang N, Li W, et al (2014). Caveolin-1 mediates chemoresistance in breast cancer stem cells via -catenin/ ABCG2 signaling pathway. Carcinogenesis, 35, 2346-56. DOI |
94 | Weigelt B, Geyer FC, Natrajan R, et al (2010). The molecular underpinning of lobular histological growth pattern: A genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol, 220, 45-57. DOI |
95 | Williams TM, Lee H, Cheung MW, et al (2004). Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis. Role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Bioll Chem, 279, 24745-56. DOI |
96 | Williams TM, Lisanti MP, (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol, 288, 494-506. |
97 | Williams TM, Lisanti MP, (2004). The caveolin proteins. Genome Biol, 5, 214. DOI |
98 | Witkiewicz AK, Dasgupta A, Sotgia F, et al (2009). An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol, 174, 2023-34. DOI |